Kalaris Therapeutics
Price & Volume
Stats
See more52W Range | $2.14-$11.88 |
Market Cap | $132.2M |
Shares Short | 919,448 |
Financials
See moreRevenue (12 Mos) | $0 |
Revenue Growth (YoY) | 0% |
Gross Profit (12 Mos) | $0 |
Diluted EPS | -$2.85 |
News
See moreYahoo Finance • 3 months ago
Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement
Yahoo Finance • 7 months ago
UPDATE – Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration
Yahoo Finance • 8 months ago
Kalaris Reports Second Quarter 2025 Financial Results and Provides Business Updates
Yahoo Finance • 8 months ago
Piper Sandler assumes coverage of Kalaris stock with Neutral rating
About
CEO | Mr. Andrew Oxtoby |
CFO | Mr. Matthew Gall M.B.A. |
Address | 400 Connell Drive, Berkeley Heights, NJ, United States, 07922 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 20 |
